Jennifer Brown is a postdoctoral scientist conducting clinical, epidemiological, and implementation research aimed at informing HIV management in Southern and East Africa. Key interests include paediatric HIV, viral drug resistance, implementation of genotypic resistance testing, treatment outcome monitoring strategies, decentralisation of service delivery, and the rollout of new antiretrovirals (notably dolutegravir).
UNIverse - Public Research Portal
Selected Publications
, Ringera, Isaac Kaumbuthu, Luoga, Ezekiel, Bresser, Moniek, Mothobi, Buoang, Kabundi, Lorraine, Ilunga, Mulume, Mokhele, Kuena, Isaac, Andreas Boy, Tsoaeli, Ntsepiseng, Mbaya, Thomas, Simba, Brenda, Mayogu, Kasasi, Mabula, Elizabeth, Cheleboi, Molisana, Molatelle, Mamello, Kimera, Namvua, Mollel, Getrud Joseph, Sando, David, et al. (2024). Resistance-informed versus empirical management of viraemia in children and adolescents with HIV in Lesotho and Tanzania (GIVE MOVE trial): a multisite, open-label randomised controlled trial [Journal-article]. The Lancet Global Health, 12(8), e1312–e1322. https://doi.org/10.1016/s2214-109x(24)00183-9
, Ringera, Isaac Kaumbuthu, Luoga, Ezekiel, Bresser, Moniek, Mothobi, Buoang, Kabundi, Lorraine, Ilunga, Mulume, Mokhele, Kuena, Isaac, Andreas Boy, Tsoaeli, Ntsepiseng, Mbaya, Thomas, Simba, Brenda, Mayogu, Kasasi, Mabula, Elizabeth, Cheleboi, Molisana, Molatelle, Mamello, Kimera, Namvua, Mollel, Getrud Joseph, Sando, David, et al. (2024). Resistance-informed versus empirical management of viraemia in children and adolescents with HIV in Lesotho and Tanzania (GIVE MOVE trial): a multisite, open-label randomised controlled trial [Journal-article]. The Lancet Global Health, 12(8), e1312–e1322. https://doi.org/10.1016/s2214-109x(24)00183-9
Tschumi, Nadine, Lukau, Blaise, Tlali, Katleho, Motaboli, Lipontso, Kao, Mpho, Kopo, Mathebe, Hänggi, Kathrin, Mokebe, Moleboheng, Naegele, Klaudia, Ayakaka, Irene, Leuzinger, Karoline, , & Labhardt, Niklaus D. (2024). Emergence of acquired dolutegravir resistance in treatment-experienced people with HIV in Lesotho [Journal-article]. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae185
Tschumi, Nadine, Lukau, Blaise, Tlali, Katleho, Motaboli, Lipontso, Kao, Mpho, Kopo, Mathebe, Hänggi, Kathrin, Mokebe, Moleboheng, Naegele, Klaudia, Ayakaka, Irene, Leuzinger, Karoline, , & Labhardt, Niklaus D. (2024). Emergence of acquired dolutegravir resistance in treatment-experienced people with HIV in Lesotho [Journal-article]. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae185
, Hauser A, Abela IA, Pasin C, Epp S, Mohloanyane T, Nsakala BL, Trkola A, Labhardt ND, Kouyos RD, & Günthard HF. (2023). Seroprofiling of Antibodies Against Endemic Human Coronaviruses and Severe Acute Respiratory Syndrome Coronavirus 2 in a Human Immunodeficiency Virus Cohort in Lesotho: Correlates of Antibody Response and Seropositivity. The Journal of Infectious Diseases, 228(8), 1042–1054. https://doi.org/10.1093/infdis/jiad197
, Hauser A, Abela IA, Pasin C, Epp S, Mohloanyane T, Nsakala BL, Trkola A, Labhardt ND, Kouyos RD, & Günthard HF. (2023). Seroprofiling of Antibodies Against Endemic Human Coronaviruses and Severe Acute Respiratory Syndrome Coronavirus 2 in a Human Immunodeficiency Virus Cohort in Lesotho: Correlates of Antibody Response and Seropositivity. The Journal of Infectious Diseases, 228(8), 1042–1054. https://doi.org/10.1093/infdis/jiad197
Tschumi N, Lerotholi M, Motaboli L, Mokete M, Labhardt ND, & . (2023). Two-year outcomes of treatment-experienced adults after programmatic transitioning to dolutegravir: longitudinal data from the VICONEL HIV cohort in Lesotho. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. https://doi.org/10.1093/cid/ciad390
Tschumi N, Lerotholi M, Motaboli L, Mokete M, Labhardt ND, & . (2023). Two-year outcomes of treatment-experienced adults after programmatic transitioning to dolutegravir: longitudinal data from the VICONEL HIV cohort in Lesotho. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. https://doi.org/10.1093/cid/ciad390
, Nsakala, Bienvenu L., Mokhele, Kuena, Rakuoane, Itumeleng, Muhairwe, Josephine, Urda, Lorena, Amstutz, Alain, Tschumi , Nadine, Klimkait, Thomas, & Labhardt, Niklaus D. (2022). Viral suppression after transition from nonnucleoside reverse transcriptase inhibitor- to dolutegravir-based antiretroviral therapy: a prospective cohort study in Lesotho (DO-REAL study). HIV medicine, 23(3), 287–293. https://doi.org/10.1111/hiv.13189
, Nsakala, Bienvenu L., Mokhele, Kuena, Rakuoane, Itumeleng, Muhairwe, Josephine, Urda, Lorena, Amstutz, Alain, Tschumi , Nadine, Klimkait, Thomas, & Labhardt, Niklaus D. (2022). Viral suppression after transition from nonnucleoside reverse transcriptase inhibitor- to dolutegravir-based antiretroviral therapy: a prospective cohort study in Lesotho (DO-REAL study). HIV medicine, 23(3), 287–293. https://doi.org/10.1111/hiv.13189
